Any of the following:\r\n* Individuals/or persons who are nursing\r\n* Individual/or persons who are pregnant\r\n* Individuals/or persons of childbearing potential who are unwilling to employ adequate contraception
History of, or active autoimmune disease (e.g., autoimmune neutropenia, thrombocytopenia, or hemolytic anemia, systemic lupus erythematosus, Sjogren´s syndrome, scleroderma, myasthenia gravis, Goodpasture´s syndrome, Addison´s disease, Hashimoto’s thyroiditis, or Grave's disease) as determined by the treating medical oncologist\r\n* Persons with vitiligo are not excluded\r\n* Persons with a history of type 1 diabetes are not excluded if the condition is well controlled:\r\n** Hemoglobin A1C < 7.0, and\r\n** No evidence of end-organ damage due to diabetes, such as diabetic retinopathy, nephropathy, or neuropathy\r\n** Persons with type 2 diabetes are not excluded since this is not an autoimmune disease, and do not need to meet these criteria\r\n* Persons with hypothyroidism are not excluded if condition is well controlled, and condition is due to a non-autoimmune etiology
Any of the following:\r\n* Pregnant persons\r\n* Nursing persons
Any of the following:\r\n* Pregnant persons\r\n* Nursing persons\r\n* Persons of childbearing potential who are unwilling to employ adequate contraception for at least 3 months after the last dose of the study drug
Persons who are incarcerated or otherwise under compulsory detention by an authority are not eligible
Any of the following:\r\n* Pregnant persons\r\n* Nursing persons\r\n* Persons of childbearing potential who are unwilling to employ adequate contraception
Any of the following:\r\n* Pregnant persons or persons of reproductive ability who are unwilling to use effective contraception\r\n* Nursing persons
Persons with an infection that is not responding to antimicrobial therapy
Persons with uncontrolled central nervous system malignancy
Persons who do not meet the age and organ function criteria specified above
Any of the following:\r\n* Pregnant persons\r\n* Nursing persons\r\n* Persons of childbearing potential who are unwilling to employ adequate contraception
Any of the following:\r\n* Pregnant persons\r\n* Nursing persons\r\n* Persons of childbearing potential who are unwilling to employ adequate contraception
Any of the following\r\n* Pregnant persons\r\n* Nursing persons\r\n* Persons of childbearing potential who are unwilling to employ adequate contraception
Any of the following:\r\n* Pregnant individuals\r\n* Nursing individuals\r\n* Persons of childbearing potential who are unwilling to employ adequate contraception
Brain tumor that is not measurable on MRI or persons who are unable to have MRIs
Any of the following:\r\n* Pregnant persons\r\n* Nursing persons\r\n* Persons of childbearing potential who are unwilling to employ adequate contraception
Persons with positive sentinel nodes must have a complete lymphadenectomy
COHORT A: Persons of reproductive potential unwilling to use an adequate method of contraception throughout treatment and for at least 26 weeks after ipilimumab is stopped
COHORT B: Persons of reproductive potential unwilling to use an adequate method of contraception throughout treatment and for at least 26 weeks after ipilimumab is stopped
Persons of reproductive potential must agree to use an adequate method of contraception throughout treatment and for at least 8 weeks after ipilimumab is stopped
Any of the following:\r\n* Pregnant persons\r\n* Nursing persons\r\n* Persons of childbearing potential who are unwilling to employ adequate contraception; Note: persons of childbearing potential and persons able to father a child who are sexually active must be practicing a highly effective method of birth control during and after the study consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trials; subjects must agree to not donate sperm during and after the study; for persons of childbearing potential, these restrictions apply for 1 month after the last dose of study drug; for persons able to father a child, these restrictions apply for 3 months after the last dose of study drug
Persons with acute cardiac or respiratory medical conditions, or who are pregnant/breastfeeding will not be eligible for participation
Persons who do not meet the eligibility criteria of any of the trials open to accrual will be excluded from participation, and persons who may be eligible (e.g., disease/histology, stage, prior treatment) but do not meet additional trial-specific requirements such as insurance or allergy to drug)
